Catalog No.: PC-23692Not For Human Use, Lab Use Only.
IRX5010 (IRX4647F) is a second generation, potent, highly selective RARγ agonist with EC50 of <0.1 nM in RARγ transactivation reporter assays, >1000-fold selective over RARα.
IRX5010 (IRX4647F) is a second generation, potent, highly selective RARγ agonist with EC50 of <0.1 nM in RARγ transactivation reporter assays, >1000-fold selective over RARα.
IRX5010 demonstrates no significant inhibitory activity in vitro on EMT-6 proliferation at concentrations lower than 20-100 uM.
IRX5010 demonstrates substantial dose dependent treatment effects relative to vehicle control (59-73%) on inhibition of growth of EMT-6 syngeneic murine triple negative breast cancer in vivo.
IRX5010 induces tumor infiltrating T-lymphocytes of effector memory phenotypes, demonstrating immunity promoting effects in the tumor immune microenvironment.
